Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2018 By Key Players : Eli Lilly, GSK, Sanofi, AstraZeneca

Qyresearchreports include new market research report "Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research Report 2018" to its huge collection of research reports.

The global market for Glucagon Like Peptide-1 (GLP-1) Agonists has been significantly growing and its demand is increasing globally due to the positive factors that drive the market is its favor. The report that have a global platform helps the decision makers to take reliable decisions that deal with specified industry clients. Although the concentration is on the stakeholders that are connected through a value chain in the market but sometimes government agencies and venture capitalists also requires the specifications of a certain market.

Enter your information below to receive a free sample copy of this report @ https://www.qyresearchreports.com/sample/sample.php?rep_id=1832740&type=S

This report studies the global Glucagon Like Peptide-1 (GLP-1) Agonists market status and forecast, categorizes the global Glucagon Like Peptide-1 (GLP-1) Agonists market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.

The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is valued at 5240 million US$ in 2017 and will reach 14200 million US$ by the end of 2025, growing at a CAGR of 13.3% during 2018-2025.

The major manufacturers covered in this report
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
North America
Europe
China
Japan
Southeast Asia
India

View TOC (table of content) of the Report: https://www.qyresearchreports.com/report/global-glucagon-like-peptide-1-glp-1-agonists-market-research-report-2018.htm/toc

Key Stakeholders
Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers
Glucagon Like Peptide-1 (GLP-1) Agonists Distributors/Traders/Wholesalers
Glucagon Like Peptide-1 (GLP-1) Agonists Subcomponent Manufacturers
Industry Association
Downstream Vendors

Table of Contents

1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
1.1 Product Overview and Scope of Glucagon Like Peptide-1 (GLP-1) Agonists
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type (Product Category)
1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Region (2013-2025)
1.5 Global Market Size (Value) of Glucagon Like Peptide-1 (GLP-1) Agonists (2013-2025)
1.5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Status and Outlook (2013-2025)
1.5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Capacity, Production Status and Outlook (2013-2025)

2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Competition by Manufacturers
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Capacity, Production and Share by Manufacturers (2013-2018)
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Share by Manufacturers (2013-2018)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Manufacturers (2013-2018)
2.4 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Sales Area and Product Type
2.5 Glucagon Like Peptide-1 (GLP-1) Agonists Market Competitive Situation and Trends

List of Tables and Figures

Figure Picture of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Production () and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Market Share by Types (Product Category) in 2017
Figure North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million USD) and Growth Rate (2013-2025)
Figure Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million USD) and Growth Rate (2013-2025)
Figure China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million USD) and Growth Rate (2013-2025)
Figure Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Million USD) and Growth Rate (2013-2025)

About Us:

QYResearchReports.com delivers the latest strategic market intelligence to build a successful business footprint in China. Our syndicated and customized research reports provide companies with vital background information of the market and in-depth analysis on the Chinese trade and investment framework, which directly affects their business operations. Reports from QYResearchReports.com feature valuable recommendations on how to navigate in the extremely unpredictable yet highly attractive Chinese market.

Contact Us:

1820 Avenue
M Suite #1047
Brooklyn, NY 11230
United States
Toll Free: 866-997-4948 (USA-CANADA)
Tel: +1-518-621-2074
Web: http://www.qyresearchreports.com

This release was published on openPR.